BSE filing, NSE: ORCHPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Orchid Pharma Ltd: key numbers
- Share price
- ₹865.00
- Market cap
- ₹5,180 Cr
- Revenue (annual)
- ₹811.3 Cr
- Net profit (annual)
- ₹20.55 Cr
- P/E (TTM)
- 597.6×Sector 46.1×
- Promoter holding
- 74.45%+4.61% QoQ
- FII holding
- 0.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Orchid Pharma Ltd
All →Orchid Pharma Partnership
Orchid Pharma entered a licensing and supply agreement with Laboratorio Libra for Exblifep across nine Latin American markets. The partnership is expected to represent a potential opportunity of about USD 80 million over 10 years.
Orchid Pharma Fund Raise of ₹600 Cr
Orchid Pharma's board approved an enabling resolution to raise funds of up to ₹600 Crore through equity or debt securities via various permissible modes.
- Value
- ₹600.0 Cr
Orchid Pharma Other Announcement
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Orchid Pharma Board Meeting Date
Orchid Pharma has scheduled a board meeting for October 20, 2026, to consider options for raising funds. The company will explore various suitable funding avenues.
Orchid Pharma Other Announcement
Orchid Pharma Ltd has filed its quarterly Shareholding Pattern, providing a routine update on promoter and public shareholding as mandated by SEBI regulations.
Orchid Pharma Annual General Meeting
Orchid Pharma held its 33rd Annual General Meeting on September 29, 2026, where shareholders considered and approved routine business resolutions and related party transactions.
Other acquisition announcements
All →MosChip Technologies Acquisition Worth ₹266.7 Cr
MosChip will acquire Vayavya Labs for Rs.266.71 Crore in cash and shares. Completion awaits RBI and exchange approvals and shareholder approval of a preferential issue.
- Value
- ₹266.7 Cr
- Execution
- Within 15 days of the later of receipt of all requisite approvals or shareholder approval of the preferential issue to VLPL sellers
Hexaware Technologies Acquisition
Hexaware Technologies announced amalgamation of two wholly owned step-down subsidiaries into its Canadian subsidiary. No cash consideration is involved, and the merger is internal group restructuring.
Zensar Technologies Acquisition
Zensar's board approved merging its wholly owned subsidiary M3bi India into the parent. No consideration or share issuance is involved, and NCLT sanction is pending.
ICICI Lombard General Insurance Company Acquisition Worth ₹172 Cr
ICICI Lombard disclosed that it acquired Rs.172 Crore of State Bank of India shares on October 28, 2026, in its ordinary-course investment function. Its cumulative holding in SBI is now 0.02%.
- Value
- ₹172.0 Cr
- Execution
- Investment made in multiple tranches over a period of time
Emkay Global Financial Services Acquisition Worth ₹30 Cr
Emkay Global will buy Emkay Capital Private Limited for Rs 30 Crore in cash. The related-party deal is expected to complete within 90 days.
- Value
- ₹30.00 Cr
Jindal Stainless Acquisition Worth ₹5.08 Cr
Jindal Stainless acquired an additional ~7% stake in Ampin C&I Three, taking its holding to 24.21%. The cash cost is ~₹5.08 crore for a 40 MW captive solar project.
- Value
- ₹5.08 Cr
- solar captive capacity
- 40.0 MW